Ethnobotanical significance of medicinal plants: Beta-amyloid and tau aggregation inhibitors against Alzheimer's disease

被引:6
|
作者
Ganapathy, A. Anand [1 ,2 ]
Haripriya, Vijayakumari M. M. [1 ,2 ]
Acharya, Niyati [3 ]
Somappa, Sasidhar B. B. [1 ,2 ]
Kumaran, Alaganandam [1 ,2 ]
机构
[1] CSIR Natl Inst Interdisciplinary Sci & Technol, Div Chem Sci & Technol, Thiruvananthapuram 695019, India
[2] Acad Sci & Innovat Res AcSIR, Ghaziabad, India
[3] Nirma Univ, Inst Pharm, Ahmadabad, Gujarat, India
关键词
Alzheimer's disease; beta-amyloid; ethnobotany; phytochemistry; tau; LONICERA JAPONICA THUNB; CLEAVING ENZYME 1; IN-VITRO; PROTEIN HYPERPHOSPHORYLATION; SCUTELLARIA-BAICALENSIS; FIBRIL FORMATION; GINSENOSIDE RD; GINKGO-BILOBA; PC12; CELLS; EXTRACT;
D O I
10.1002/jbt.23339
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Among the various neurodegenerative disorders, Alzheimer's disease (AD) is identified as one of primary causes of dementia in the elderly, which progresses slowly leading to cognitive decline and ability to function independently. Although various pathological mechanisms have been proposed, the exact mechanism is not yet elucidated. Numerous processes such as old age, mitochondrial dysfunction, and genetics lead to the aggregation of beta-amyloid (A beta) as amyloid plaques and tau proteins as neurofibrillary tangles in the neurons leading to their death and destruction, finally leading to AD. The current treatment measures can only temporarily improve the symptoms, slowing cognitive decline without any effect on AD pathology for better therapeutic effect. Furthermore, the high failure rates of a number of drugs during clinical trials due to their side effects has led the researchers to focus on alternative sources for drug development. As natural ingredients were considered the primary line of treatment in the olden days, and as several medicinal plant products are also proven as effective AD targets, it will be wise to investigate those with significant ethnobotanical value as potential neuroprotectives, nootropics or memory boosters. Throughout the study, propanoids, glycosides, iridoids, carotenoids and flavonoids that show potential anti-inflammatory, antioxidant, and anti-cholinesterase were also found to be inhibitors of A beta and tau aggregation, where Saikosaponin C, Fisetin, and Morin can act as dual inhibitors. The review provides an insight in the need for proper and complete scientific evaluation of these ethnobotanically useful medicinal plants to be identified as potential leads in AD therapy.
引用
收藏
页数:30
相关论文
共 50 条
  • [21] Beta Amyloid Aggregation Inhibitors: Small Molecules as Candidate Drugs for Therapy of Alzheimer's Disease
    Re, F.
    Airoldi, C.
    Zona, C.
    Masserini, M.
    La Ferla, B.
    Quattrocchi, N.
    Nicotra, F.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (27) : 2990 - 3006
  • [22] Tau oligomers and aggregation in Alzheimer's disease
    Meraz-Rios, Marco A.
    Lira-De Leon, Karla I.
    Campos-Pena, Victoria
    De Anda-Hernandez, Martha A.
    Mena-Lopez, Raul
    JOURNAL OF NEUROCHEMISTRY, 2010, 112 (06) : 1353 - 1367
  • [23] Polyphenols as potential inhibitors of amyloid aggregation and toxicity: Possible significance to Alzheimer's disease
    Bastianetto, S.
    Krantic, S.
    Quirion, R.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2008, 8 (05) : 429 - 435
  • [24] The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer’s disease: a longitudinal PET study
    Rola Ismail
    Peter Parbo
    Lasse Stensvig Madsen
    Allan K. Hansen
    Kim V. Hansen
    Jeppe L. Schaldemose
    Pernille L. Kjeldsen
    Morten G. Stokholm
    Hanne Gottrup
    Simon F. Eskildsen
    David J. Brooks
    Journal of Neuroinflammation, 17
  • [25] beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease
    Cummings, BJ
    Pike, CJ
    Shankle, R
    Cotman, CW
    NEUROBIOLOGY OF AGING, 1996, 17 (06) : 921 - 933
  • [26] Membrane rafts in Alzheimer's disease beta-amyloid production
    Vetrivel, Kulandaivelu S.
    Thinakaran, Gopal
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2010, 1801 (08): : 860 - 867
  • [27] Absence of beta-amyloid in cortical cataracts of donors with and without Alzheimer's disease
    Michael, Ralph
    Rosandic, Jurja
    Montenegro, Gustavo A.
    Lobato, Elvira
    Tresserra, Francisco
    Barraquer, Rafael I.
    Vrensen, Gijs F. J. M.
    EXPERIMENTAL EYE RESEARCH, 2013, 106 : 5 - 13
  • [28] Platelets: Their Potential Contribution to the Generation of Beta-amyloid Plaques in Alzheimer's Disease
    Humpel, Christian
    CURRENT NEUROVASCULAR RESEARCH, 2017, 14 (03) : 290 - 298
  • [29] Inhibitory effect of monoclonal antibodies on Alzheimer's beta-amyloid peptide aggregation
    Hanan, E
    Solomon, B
    AMYLOID-INTERNATIONAL JOURNAL OF EXPERIMENTAL AND CLINICAL INVESTIGATION, 1996, 3 (02): : 130 - 133
  • [30] Aggregation of beta-amyloid peptide is promoted by membrane phospholipid metabolites elevated in Alzheimer's disease brain
    Klunk, WE
    Xu, CJ
    McClure, RJ
    Panchalingam, K
    Stanley, JA
    Pettegrew, JW
    JOURNAL OF NEUROCHEMISTRY, 1997, 69 (01) : 266 - 272